Effects of de-facing software mri_reface on utility of imaging biomarkers used in Alzheimer’s disease research
Year: 2023
Type: article
Abstract: Brain imaging research studies increasingly use "de-facing" software to remove or replace facial imagery before public data sharing. Several works have studied the effects of de-facing software on brain imaging biomarkers by directly comparing automated measurements from unmodified vs de-faced images, but most research brain images are used in analyses of correlations with cognitive measurements or clinical statuses, and the effects of de-facing on these types of imaging-to-cognition correlations has not been measured. In this work, we focused on brain imaging measures of amyloid (A), tau (T), neurodegeneration (N), and vascular (V) measures used in Alzheimer's Disease (AD) research. We created a retrospective sample of participants from three age- and sex-matched clinical groups (cognitively unimpaired, mild cognitive impairment, and AD dementia, and we performed region- and voxel-wise analyses of: hippocampal volume (N), white matter hyperintensity volume (V), amyloid PET (A), and tau PET (T) measures, each from multiple software pipelines, on their ability to separate cognitively defined groups and their degrees of correlation with age and Clinical Dementia Rating (CDR)-Sum of Boxes (CDR-SB). We performed each of these analyses twice: once with unmodified images and once with images de-faced with leading de-facing software mri_reface, and we directly compared the findings and their statistical strengths between the original vs. the de-faced images. Analyses with original and with de-faced images had very high agreement. There were no significant differences between any voxel-wise comparisons. Among region-wise comparisons, only three out of 55 correlations were significantly different between original and de-faced images, and these were not significant after correction for multiple comparisons. Overall, the statistical power of the imaging data for AD biomarkers was almost identical between unmodified and de-faced images, and their analyses results were extremely consistent.
Source: NeuroImage Clinical
Institution: Mayo Clinic
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,400
Funders: Mayo Clinic, Mayo Foundation for Medical Education and Research, GHR Foundation, Elsie and Marvin Dekelboum Family Foundation, Schuler-Stiftung, National Institutes of Health, U.S. Food and Drug Administration, Avid Radiopharmaceuticals, National Institute on Aging, National Institute of Neurological Disorders and Stroke
Awards: Multimorbidity and Aging: Rochester Epidemiology Project, Alzheimers Disease Patient Registry, G3930010334, G4741916379, G5484535055, G5900136256, Protecting the Confidentiality of Participants in Studies of Alzheimer's Disease and Related Dementias by Replacing Face Imagery in MRI, G6875889451, Development, Validation, and Application of an Imaging based CVD Scale, Protecting the Confidentiality of Participants in Studies of Alzheimer's Disease and Related Dementias by Replacing Face Imagery in MRI, G824560934, Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system, G8611190880, G9000005508, G9000338148, Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkers, Investigating Resistance and Resilience Mechanisms in Alzheimer’s Disease, Longitudinal Imaging Biomarkers of Prodromal DLB, Mayo Alzheimer's Disease Research Center
OpenAlex ID: W4386571041
